Glossary

Methotrexate Monitoring

Methotrexate monitoring is the regular blood testing for people taking low-dose methotrexate, usually for Rheumatoid Arthritis, Psoriasis or Inflammatory Bowel Disease. It looks for effects on the blood count, liver and kidneys, and goes alongside the safety rules for once-weekly dosing.

Clinically reviewed by Aisha Malik, Clinical Director (GPhC 2205843), on .

What it means in practice

SPS guidance lists baseline tests before starting, including a full blood count, liver function tests, kidney function, albumin, blood pressure, weight and height, and screening for hepatitis B and C and HIV. After starting or changing the dose, the full blood count, liver function tests and kidney function are checked every 1 to 2 weeks in its general guidance, with specialty schedules that differ; once stable, checks are every 2 to 3 months, or at least every 12 weeks in rheumatology. SPS lists results that should prompt stopping and contacting the specialist, and notes that a falling count or rising liver enzymes can signal toxicity even within the normal range. SPS is updating its entry to match the British Society for Rheumatology guideline published in November 2025. The MHRA has also asked prescribers to check patients understand once-weekly dosing, because taking methotrexate daily by mistake has caused fatal overdoses.

Good practice

  • Keep a register of everyone on methotrexate with the date of their last bloods
  • Follow the monitoring schedule in the shared care agreement or the specialist's letter
  • Look at trends in results, not just whether each one is in range
  • Make sure every prescription states once weekly and the day it is taken
  • Contact the specialist when results meet the stop criteria

Questions

How often are bloods needed on methotrexate?

Every 1 to 2 weeks after starting or changing the dose in SPS's general guidance, then every 2 to 3 months once stable. Specialties differ: in rheumatology it is at least every 12 weeks once stable. Follow the shared care agreement for the patient.

Why is once-weekly dosing so important?

The MHRA has reported fatal overdoses when methotrexate meant for once-weekly use was taken daily. Prescribers should check the patient understands once-weekly dosing and warn them and their carers of the risk.

Sources

Checked against these sources on 20 November 2026.

  1. Methotrexate monitoring (SPS)
  2. Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose (MHRA Drug Safety Update)

Remote clinical pharmacists, funded through ARRS.

Book a 30-minute call